Literature DB >> 24313854

Increased soluble C5b-9 in CSF of neuromyelitis optica.

H Wang1, K Wang, C Wang, W Qiu, Z Lu, X Hu.   

Abstract

Neuromyelitis optica (NMO) and multiple sclerosis (MS) are two of the autoimmune inflammatory demyelinating diseases in the central nervous system. Complement is thought to have an important role in pathogenesis of these diseases, especially in NMO. However, the change of terminal complement complex (TCC, C5b-9) in patients with NMO is still unclear. Cerebrospinal fluid (CSF) C3a, C5a, sC5b-9 were measured by enzyme-linked immunosorbent assay in patients with NMO (n = 26), MS (n = 25) and other neurological disease (OND, n = 19). CSF levels of C5a in patients with NMO were higher than patients with OND (P = 0.006). Increased CSF sC5b-9 were found in the patients with NMO compared with patients with MS (P = 0.029) and OND (P = 0.0001). CSF sC5b-9 in patients with MS were also higher than patients with OND (P = 0.030). Patients with NMO revealed a trend to an increased disease disability with increased CSF sC5b-9 during relapse but not in MS (NMO: P = 0.006, MS: P = 0.097). CSF levels of sC5b-9 are increased in patients with NMO and reflect the activation of complement in NMO.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24313854     DOI: 10.1111/sji.12132

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  9 in total

Review 1.  The complement system as a biomarker of disease activity and response to treatment in multiple sclerosis.

Authors:  Alexandru Tatomir; Anamaria Talpos-Caia; Freidrich Anselmo; Adam M Kruszewski; Dallas Boodhoo; Violeta Rus; Horea Rus
Journal:  Immunol Res       Date:  2017-12       Impact factor: 2.829

Review 2.  Targeting Neuromyelitis Optica Pathogenesis: Results from Randomized Controlled Trials of Biologics.

Authors:  Laura Cacciaguerra; Paola Tortorella; Maria A Rocca; Massimo Filippi
Journal:  Neurotherapeutics       Date:  2021-04-28       Impact factor: 6.088

Review 3.  Targeting the complement system in neuromyelitis optica spectrum disorder.

Authors:  Nithi Asavapanumas; Lukmanee Tradtrantip; Alan S Verkman
Journal:  Expert Opin Biol Ther       Date:  2021-02-16       Impact factor: 5.589

4.  Comparison of clinical characteristics between neuromyelitis optica spectrum disorders with and without spinal cord atrophy.

Authors:  Yanqiang Wang; Aimin Wu; Xiaoyu Chen; Lei Zhang; Yinyao Lin; Shaoyang Sun; Wei Cai; Bingjun Zhang; Zhuang Kang; Wei Qiu; Xueqiang Hu; Zhengqi Lu
Journal:  BMC Neurol       Date:  2014-12-20       Impact factor: 2.474

5.  Impact of complement activation on clinical outcomes in multiple sclerosis.

Authors:  Christian W Keller; Johanna Oechtering; Heinz Wiendl; Ludwig Kappos; Jens Kuhle; Jan D Lünemann
Journal:  Ann Clin Transl Neurol       Date:  2021-03-01       Impact factor: 4.511

Review 6.  Serum and Cerebrospinal Fluid Biomarkers in Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Associated Disease.

Authors:  Alessandro Dinoto; Elia Sechi; Eoin P Flanagan; Sergio Ferrari; Paolo Solla; Sara Mariotto; John J Chen
Journal:  Front Neurol       Date:  2022-03-23       Impact factor: 4.003

Review 7.  Soluble Membrane Attack Complex: Biochemistry and Immunobiology.

Authors:  Scott R Barnum; Doryen Bubeck; Theresa N Schein
Journal:  Front Immunol       Date:  2020-11-10       Impact factor: 7.561

Review 8.  Complement in neurological disorders and emerging complement-targeted therapeutics.

Authors:  Marinos C Dalakas; Harry Alexopoulos; Peter J Spaeth
Journal:  Nat Rev Neurol       Date:  2020-10-01       Impact factor: 42.937

Review 9.  Complement Factor D as a Strategic Target for Regulating the Alternative Complement Pathway.

Authors:  Jonathan Barratt; Ilene Weitz
Journal:  Front Immunol       Date:  2021-09-09       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.